Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Pieris Pharmaceuticals Inc (PIRS)

Pieris Pharmaceuticals Inc (PIRS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
13.60 -2.53 (-15.69%) 12/13/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 13.60 unch (unch) -
Quote Overview for Fri, Dec 13th, 2024
Day Low
13.26
Day High
15.35
Open 15.01
Previous Close 16.13 16.13
Volume 51,700 51,700
Avg Vol 21,120 21,120
Stochastic %K 29.42% 29.42%
Weighted Alpha -50.53 -50.53
5-Day Change -2.73 (-16.72%) -2.73 (-16.72%)
52-Week Range 6.20 - 22.32 6.20 - 22.32
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,955
  • Shares Outstanding, K 1,320
  • Annual Sales, $ 42,810 K
  • Annual Income, $ -24,540 K
  • EBIT $ -26 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.61
  • Price/Sales 0.50
  • Price/Cash Flow N/A
  • Price/Book 1.10
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -19.51
  • Most Recent Earnings $-2.19 on 11/13/24
  • Next Earnings Date 11/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.26 +2.56%
on 12/13/24
Period Open: 16.10
17.36 -21.66%
on 12/10/24
-2.50 (-15.53%)
since 11/13/24
3-Month
13.26 +2.56%
on 12/13/24
Period Open: 16.67
17.70 -23.16%
on 11/06/24
-3.07 (-18.42%)
since 09/13/24
52-Week
6.20 +119.35%
on 07/12/24
Period Open: 11.20
22.32 -39.07%
on 03/18/24
+2.40 (+21.43%)
since 12/13/23

Most Recent Stories

More News
Pieris Pharmaceuticals: Q3 Earnings Snapshot

Pieris Pharmaceuticals: Q3 Earnings Snapshot

PIRS : 13.60 (-15.69%)
Pieris Pharmaceuticals: Q2 Earnings Snapshot

Pieris Pharmaceuticals: Q2 Earnings Snapshot

PIRS : 13.60 (-15.69%)
Pieris Pharmaceuticals: Q1 Earnings Snapshot

Pieris Pharmaceuticals: Q1 Earnings Snapshot

PIRS : 13.60 (-15.69%)
Pieris Pharmaceuticals: Q3 Earnings Snapshot

Pieris Pharmaceuticals: Q3 Earnings Snapshot

PIRS : 13.60 (-15.69%)
Pieris Pharmaceuticals: Q1 Earnings Snapshot

Pieris Pharmaceuticals: Q1 Earnings Snapshot

PIRS : 13.60 (-15.69%)
Pieris Pharmaceuticals: Q3 Earnings Snapshot

Pieris Pharmaceuticals: Q3 Earnings Snapshot

PIRS : 13.60 (-15.69%)
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 13.60 (-15.69%)
Chau Khuong Joins Catalio Capital Management as General Partner

Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced that Chau Khuong, who was most recently a Partner at OrbiMed Advisors, has joined...

FUSN : 21.55 (+0.14%)
GKOS : 97.09 (-1.35%)
NTLA : 6.66 (-6.40%)
ICPT : 19.00 (+0.21%)
INSP : 157.98 (-0.82%)
NXTC : 0.4370 (-9.02%)
PIRS : 13.60 (-15.69%)
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 13.60 (-15.69%)
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology...

PIRS : 13.60 (-15.69%)

Business Summary

Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.

See More

Key Turning Points

3rd Resistance Point 16.97
2nd Resistance Point 16.16
1st Resistance Point 14.88
Last Price 13.60
1st Support Level 12.79
2nd Support Level 11.98
3rd Support Level 10.70

See More

52-Week High 22.32
Fibonacci 61.8% 16.16
Fibonacci 50% 14.26
Last Price 13.60
Fibonacci 38.2% 12.36
52-Week Low 6.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies